08:22 AM EDT, 04/07/2025 (MT Newswires) -- Zevra Therapeutics ( ZVRA ) said Monday that it has completed the sale of a rare pediatric disease priority review voucher for $150 million in gross proceeds.

Zevra had received the voucher last year following US regulatory approval of its therapy for Niemann-Pick type C, Miplyffa, the commercial-stage company said.

The funds will be used to support the commercial launches of Miplyffa and Olpruva, ongoing clinical studies on celiprolol, and overall investment plans, the company said.

As of March 31, Zevra reported preliminary cash and equivalents of $68.7 million, which would rise to $217 million after accounting for post-quarter net proceeds from the sale.

Shares of the company were down more than 3.5% in recent Monday premarket activity.